DB:ZRE

Stock Analysis Report

Executive Summary

Zur Rose Group AG, an online pharmacy company, wholesales products to medical practitioners under the Zur Rose and DocMorris brands in Germany and Austria.


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

Share Price & News

How has Zur Rose Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ZRE has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

ZRE

3.7%

DE Consumer Retailing

7.1%

DE Market


1 Year Return

-19.8%

ZRE

-9.4%

DE Consumer Retailing

-17.5%

DE Market

Return vs Industry: ZRE underperformed the German Consumer Retailing industry which returned 4.8% over the past year.

Return vs Market: ZRE underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

ZREIndustryMarket
7 Day0%3.7%7.1%
30 Day0%-4.5%-20.0%
90 Day4.1%-11.4%-26.1%
1 Year-15.0%-19.8%-5.9%-9.4%-15.0%-17.5%
3 Yearn/a-3.3%-12.8%-18.8%-25.8%
5 Yearn/a-4.7%-19.3%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Zur Rose Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Zur Rose Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ZRE (€91.7) is trading below our estimate of fair value (€232.49)

Significantly Below Fair Value: ZRE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ZRE is unprofitable, so we can't compare its PE Ratio to the Consumer Retailing industry average.

PE vs Market: ZRE is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZRE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZRE is overvalued based on its PB Ratio (1.7x) compared to the XE Consumer Retailing industry average (1.6x).


Next Steps

Future Growth

How is Zur Rose Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

70.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZRE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: ZRE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ZRE's is expected to become profitable in the next 3 years.

Revenue vs Market: ZRE's revenue (19% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: ZRE's revenue (19% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZRE's Return on Equity is forecast to be low in 3 years time (10%).


Next Steps

Past Performance

How has Zur Rose Group performed over the past 5 years?

-54.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZRE is currently unprofitable.

Growing Profit Margin: ZRE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZRE is unprofitable, and losses have increased over the past 5 years at a rate of -54.3% per year.

Accelerating Growth: Unable to compare ZRE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZRE is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Retailing industry (0.5%).


Return on Equity

High ROE: ZRE has a negative Return on Equity (-8.67%), as it is currently unprofitable.


Next Steps

Financial Health

How is Zur Rose Group's financial position?


Financial Position Analysis

Short Term Liabilities: ZRE's short term assets (CHF292.8M) exceed its short term liabilities (CHF198.8M).

Long Term Liabilities: ZRE's short term assets (CHF292.8M) exceed its long term liabilities (CHF171.4M).


Debt to Equity History and Analysis

Debt Level: ZRE's debt to equity ratio (25%) is considered satisfactory.

Reducing Debt: ZRE had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: ZRE has a low level of unsold assets or inventory.

Debt Coverage by Assets: ZRE's debt is covered by short term assets (assets are 2.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZRE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ZRE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Zur Rose Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZRE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ZRE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZRE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZRE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ZRE is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZRE's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.7yrs

Average board tenure


CEO

Walter Oberhänsli (61yo)

14.67s

Tenure

CHF1,322,000

Compensation

Mr. Walter Oberhänsli serves as the Chief Executive Officer at Zur Rose Group AG since 2005. and served as its and Executive Director. Mr. Oberhänsli served as Member of the Executive Board. He served as C ...


CEO Compensation Analysis

Compensation vs Market: Walter's total compensation ($USD1.34M) is about average for companies of similar size in the German market ($USD1.28M).

Compensation vs Earnings: Walter's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Walter Oberhänsli
CEO & Executive Director14.67yrsCHF1.32m1.54% CHF10.9m
Stefan Feuerstein
Chairman of the Board of Directorsno dataCHF325.00k0.92% CHF6.5m
Heinz Baumgartner
Non-Executive Director2.33yrsCHF119.00k0.0069% CHF48.3k
Vanessa Frey
Non-Executive Director3.67yrsCHF119.00k0.23% CHF1.6m
Volker Amelung
Non-Executive Director9.67yrsCHF145.00k0.058% CHF412.0k
Thomas Schneider
Vice Chairman of the Board of Directorsno dataCHF163.00k0.34% CHF2.4m

6.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: ZRE's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.2%.


Top Shareholders

Company Information

Zur Rose Group AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zur Rose Group AG
  • Ticker: ZRE
  • Exchange: DB
  • Founded: 1993
  • Industry: Drug Retail
  • Sector: Consumer Retailing
  • Market Cap: CHF765.155m
  • Listing Market Cap: CHF705.565m
  • Shares outstanding: 8.67m
  • Website: https://www.zurrosegroup.com

Number of Employees


Location

  • Zur Rose Group AG
  • Walzmühlestrasse 60
  • Frauenfeld
  • Thurgau
  • 8500
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ROSESWX (SIX Swiss Exchange)YesShare CapitalCHCHFJul 2017
0RRBLSE (London Stock Exchange)YesShare CapitalGBCHFJul 2017
ZREDB (Deutsche Boerse AG)YesShare CapitalDEEURJul 2017
ZRSE.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJul 2017

Biography

Zur Rose Group AG, an online pharmacy company, wholesales products to medical practitioners under the Zur Rose and DocMorris brands in Germany and Austria. The company provides medicines management services. It also operates stationary pharmacy shops. The company was formerly known as Zur Rose AG and changed its name to Zur Rose Group AG in May 2015. Zur Rose Group AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/25 22:15
End of Day Share Price2019/06/28 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.